Alembic Pharmaceuticals Limited (APLLTD.BO)
INR 1045.0
(-1.04%)
INR 1045.0
(-1.04%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 9.61 Billion INR | 33.43% |
| 2022 | 7.11 Billion INR | -24.89% |
| 2021 | 9.24 Billion INR | -40.28% |
| 2020 | 15.67 Billion INR | 27.32% |
| 2019 | 11.84 Billion INR | 37.39% |
| 2018 | 8.82 Billion INR | 38.31% |
| 2017 | 6.5 Billion INR | 4.31% |
| 2016 | 6.17 Billion INR | -38.95% |
| 2015 | 10.13 Billion INR | 148.81% |
| 2014 | 4.07 Billion INR | 13.22% |
| 2013 | 3.61 Billion INR | 37.36% |
| 2012 | 2.65 Billion INR | 13.15% |
| 2011 | 2.32 Billion INR | 40.96% |
| 2010 | 1.6 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 2.36 Billion INR | -9.38% |
| 2023 Q2 | 2.17 Billion INR | 3.59% |
| 2023 FY | - INR | 33.43% |
| 2023 Q1 | 2.1 Billion INR | 2.77% |
| 2023 Q3 | 2.69 Billion INR | 23.55% |
| 2023 Q4 | 2.6 Billion INR | -3.4% |
| 2022 Q2 | 2.31 Billion INR | 2619.39% |
| 2022 FY | - INR | -24.89% |
| 2022 Q3 | 2.35 Billion INR | 1.81% |
| 2022 Q4 | 2.04 Billion INR | -13.13% |
| 2022 Q1 | 85.1 Million INR | -95.01% |
| 2021 FY | - INR | -40.28% |
| 2021 Q2 | 2.59 Billion INR | 9.09% |
| 2021 Q1 | 2.37 Billion INR | -29.52% |
| 2021 Q3 | 2.61 Billion INR | 0.62% |
| 2021 Q4 | 1.7 Billion INR | -34.73% |
| 2020 FY | - INR | 27.32% |
| 2020 Q4 | 3.37 Billion INR | -8.22% |
| 2020 Q3 | 3.67 Billion INR | -17.7% |
| 2020 Q2 | 4.46 Billion INR | 9.56% |
| 2020 Q1 | 4.07 Billion INR | 25.35% |
| 2019 Q1 | 2.28 Billion INR | 25.79% |
| 2019 FY | - INR | 37.39% |
| 2019 Q4 | 3.25 Billion INR | -0.07% |
| 2019 Q2 | 3.45 Billion INR | 51.56% |
| 2019 Q3 | 3.25 Billion INR | -5.9% |
| 2018 Q4 | 1.81 Billion INR | -26.18% |
| 2018 Q1 | 1.51 Billion INR | -13.1% |
| 2018 Q2 | 3.04 Billion INR | 101.67% |
| 2018 Q3 | 2.45 Billion INR | -19.35% |
| 2018 FY | - INR | 38.31% |
| 2017 Q2 | 1.86 Billion INR | 83.9% |
| 2017 FY | - INR | 4.31% |
| 2017 Q4 | 1.73 Billion INR | -7.44% |
| 2017 Q3 | 1.87 Billion INR | 0.55% |
| 2017 Q1 | 1.01 Billion INR | -25.07% |
| 2016 Q1 | 1.57 Billion INR | 7.96% |
| 2016 FY | - INR | -38.95% |
| 2016 Q3 | 1.45 Billion INR | -18.29% |
| 2016 Q4 | 1.35 Billion INR | -6.98% |
| 2016 Q2 | 1.78 Billion INR | 13.22% |
| 2015 Q3 | 3.86 Billion INR | 2.92% |
| 2015 Q1 | 1.04 Billion INR | 2.48% |
| 2015 Q4 | 1.45 Billion INR | -62.27% |
| 2015 FY | - INR | 148.81% |
| 2015 Q2 | 3.75 Billion INR | 260.14% |
| 2014 Q4 | 1.01 Billion INR | 1.07% |
| 2014 Q3 | 1 Billion INR | -6.35% |
| 2014 Q2 | 1.07 Billion INR | 11.82% |
| 2014 Q1 | 962 Million INR | 1.63% |
| 2014 FY | - INR | 13.22% |
| 2013 Q2 | 929.1 Million INR | 29.94% |
| 2013 Q1 | 715 Million INR | -4.75% |
| 2013 Q3 | 1.02 Billion INR | 10.25% |
| 2013 FY | - INR | 37.36% |
| 2013 Q4 | 946.58 Million INR | -7.59% |
| 2012 FY | - INR | 13.15% |
| 2012 Q3 | 728.2 Million INR | 12.17% |
| 2012 Q4 | 750.64 Million INR | 3.08% |
| 2012 Q1 | 524.9 Million INR | 0.0% |
| 2012 Q2 | 649.2 Million INR | 23.68% |
| 2011 FY | - INR | 40.96% |
| 2010 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Ajanta Pharma Limited | 12.56 Billion INR | 23.467% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -1308.962% |
| Sigachi Industries Limited | 883.39 Million INR | -988.603% |
| Bal Pharma Limited | 345.59 Million INR | -2682.674% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | -40.152% |
| Medico Remedies Limited | 150.37 Million INR | -6295.018% |
| Lasa Supergenerics Limited | -65.08 Million INR | 14876.736% |
| Venus Remedies Limited | 711.8 Million INR | -1251.038% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 357.733% |
| Alpa Laboratories Limited | 86.12 Million INR | -11065.72% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -514.961% |
| Shilpa Medicare Limited | 2.58 Billion INR | -271.591% |
| Aarti Drugs Limited | 3.24 Billion INR | -196.023% |
| Lupin Limited | 36.96 Billion INR | 73.987% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 84.436% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 82.895% |
| Windlas Biotech Limited | 781.72 Million INR | -1130.198% |
| Suven Life Sciences Limited | -992.78 Million INR | 1068.664% |
| Eris Lifesciences Limited | 6.98 Billion INR | -37.648% |
| Valiant Laboratories Limited | 12.73 Million INR | -75390.227% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | -3.02% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 440.788% |
| Ipca Laboratories Limited | 13.29 Billion INR | 27.691% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -550.203% |
| Achyut Healthcare Limited | 524 Thousand INR | -1835148.092% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 93.05% |
| Bajaj HealthCare Limited | 444.51 Million INR | -2063.409% |
| RPG Life Sciences Limited | 1.28 Billion INR | -650.425% |
| Mankind Pharma Limited | 28.09 Billion INR | 65.77% |
| Laurus Labs Limited | 8 Billion INR | -20.119% |
| Piramal Pharma Limited | 13.05 Billion INR | 26.339% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -2135.007% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 72.531% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 15.224% |
| Unichem Laboratories Limited | 742.35 Million INR | -1195.43% |
| Sequent Scientific Limited | 549.8 Million INR | -1649.127% |
| Novartis India Limited | 1.26 Billion INR | -657.638% |
| Wanbury Limited | 985.49 Million INR | -875.829% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | -105.609% |
| Wockhardt Limited | 1.08 Billion INR | -790.435% |
| Themis Medicare Limited | 562.6 Million INR | -1609.31% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -2873.072% |
| Jubilant Pharmova Limited | 8 Billion INR | -20.119% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | -40.126% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 89.106% |
| Divi's Laboratories Limited | 25.43 Billion INR | 62.184% |
| NATCO Pharma Limited | 18.79 Billion INR | 48.834% |
| Gufic Biosciences Limited | 1.48 Billion INR | -549.564% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -268.937% |
| Ind-Swift Limited | 1.06 Billion INR | -802.921% |
| Procter & Gamble Health Limited | 3.01 Billion INR | -219.025% |
| FDC Limited | 4.4 Billion INR | -118.478% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 11724.621% |
| Granules India Limited | 8.6 Billion INR | -11.772% |
| Medicamen Biotech Limited | 245.66 Million INR | -3814.638% |
| Alkem Laboratories Limited | 24.19 Billion INR | 60.254% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -308.041% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -73523.488% |
| Brooks Laboratories Limited | 41.72 Million INR | -22946.156% |
| Megasoft Limited | 284.73 Million INR | -3277.469% |
| ZIM Laboratories Limited | 462.09 Million INR | -1981.1% |
| Strides Pharma Science Limited | 3.76 Billion INR | -155.445% |
| Neuland Laboratories Limited | 4.74 Billion INR | -102.534% |
| Morepen Laboratories Limited | 1.72 Billion INR | -457.182% |
| Hikal Limited | 2.69 Billion INR | -257.202% |
| Indoco Remedies Limited | 2.64 Billion INR | -263.298% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | -145.988% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -3245.812% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -5396.953% |
| Hester Biosciences Limited | 539.47 Million INR | -1682.62% |